| abstract |
There is described a compound of formula (I) or pharmaceutically acceptable salts thereof wherein Z is OH, C 1-6 alkoxy, -NRR or heterocyclic group; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing 1, 2, 3 or 4 nitrogen atoms, (c) an optionally substituted 5-membered monocyclic aromatic group containing a heteroatom selected from O, S and N and optionally containing 1, 2 or 3 nitrogen atoms in addition to said heteroatom, (d) an optionally substituted C 1-8 cycloalkyl and (e) an optionally substituted benzo fused heterocyclic group; R is hydrogen, alkyl or halogen; R 2 and R 3 are independently hydrogen, OH, C 1-6 alkoxy, Calkyl or C-alkyl substituted by halogen, OH, C 1-6 alkoxy or CN; X is independently selected from H, halogen, C 1-4 alkyl, halogen-substituted C-alkyl, OH, Calkoxy, halogen-substituted C 1-8 alkoxy, Calkylthio, NO, NH, di- (C 1-4 alkyl) amino and CN; and n are 0, 1, 2, 3 and 4. There is further described a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are included as pathogens. |